Discontinuation of assigned treatment during the intensive phase, and adverse events within the first 70 days after the initial dose of study drugs.

Notes: 1: The study regimen was discontinued in both participants. In one participant the re-introduction of isoniazid replicated the flu-like symptoms experienced while on the study regimen. In the other participant the re-introduction of rifapentine or pyrazinamide replicated the flu-like symptoms experienced while on the study regimen. 2: The study regimen was discontinued. The rash recurred with re-introduction of isoniazid.